Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment
- 1 April 2011
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 10 (4) , 569-579
Abstract
Recently, the anaplastic lymphoma kinase (ALK) has been found to be altered in several solid and hematologic tumors. Novel drugs targeting this tyrosine kinase receptor are under development, and early clinical trials are showing promising activity in non–small cell lung cancer patients with ALK+ tumors. Here, we review the structure and function of the ALK receptor, the mechanisms associated with its deregulation in cancer, methods for ALK detection in tumor samples, its potential as a new marker for candidate patient selection for tailored therapy, and novel drugs under development that target ALK. Mol Cancer Ther; 10(4); 569–79. ©2011 AACR.Keywords
This publication has 89 references indexed in Scilit:
- Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung CancerJournal of Thoracic Oncology, 2011
- Crizotinib inALK-Rearranged Inflammatory Myofibroblastic TumorNew England Journal of Medicine, 2010
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- A mouse model for EML4-ALK -positive lung cancerProceedings of the National Academy of Sciences, 2008
- Somatic and germline activating mutations of the ALK kinase receptor in neuroblastomaNature, 2008
- Activating mutations in ALK provide a therapeutic target in neuroblastomaNature, 2008
- Identification of ALK as a major familial neuroblastoma predisposition geneNature, 2008
- EML4–ALK fusion transcript is not found in gastrointestinal and breast cancersBritish Journal of Cancer, 2008
- Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALKProceedings of the National Academy of Sciences, 2007
- Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3Proceedings of the National Academy of Sciences, 2006